Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

2.14
-0.0500-2.28%
Post-market: 2.150.0092+0.43%19:30 EDT
Volume:2.00M
Turnover:4.36M
Market Cap:178.49M
PE:-1.53
High:2.31
Open:2.21
Low:2.10
Close:2.19
52wk High:5.55
52wk Low:1.03
Shares:83.41M
Float Shares:70.69M
Volume Ratio:0.83
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4029
EPS(LYR):-1.2813
ROE:-179.10%
ROA:-62.95%
PB:15.60
PE(LYR):-1.67

Loading ...

GordonMD Global Investments Reports $16 Million Pyxis Oncology Common Share Purchase

Reuters
·
Yesterday

Pyxis Oncology Issues Milestone-Linked Common Warrants in Public Offering

Reuters
·
Yesterday

Pyxis Oncology Announces Closing of up to $282.6 Million Public Offering

THOMSON REUTERS
·
Yesterday

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

GlobeNewswire
·
Yesterday

U.S. Stocks on the MOVE-Boeing, Robinhood, Lumentum

Reuters
·
Sep 30

Pyxis Oncology Issues 49,310,352 Common Stock Warrants in $110 Million Offering

Reuters
·
Sep 30

Pyxis Oncology Announces Pricing of up to $282.6 Million Public Offering

THOMSON REUTERS
·
Sep 30

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

GlobeNewswire
·
Sep 30

Phase 3 Financing Should Be Good News — Why Did Pyxis Stock Crash 7%?

Bellwether Stocks Movement
·
Sep 30

Pyxis Oncology Falls After Launching Equity Offering

Reuters
·
Sep 30

Pyxis Oncology announces common stock offering, no amount given

TIPRANKS
·
Sep 30

Pyxis Oncology Launches Registered Public Offering of Stock, Pre-Funded Warrants, Common Warrants

Reuters
·
Sep 30

Pyxis Oncology Announces Proposed Public Offering

THOMSON REUTERS
·
Sep 30

Pyxis Oncology : Terminates $150.00m Atm Offering, no Shares Sold to Date - SEC Filing

THOMSON REUTERS
·
Sep 30

LifeSci Capital Remains a Buy on Pyxis Oncology (PYXS)

TIPRANKS
·
Sep 26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 22

Pyxis Oncology: MICVO’s Emerging Clinical Profile and Strong Physician Receptivity Support Buy Rating and Unchanged $6 Price Target

TIPRANKS
·
Sep 17

Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright

TIPRANKS
·
Sep 10

Analyst Maintains Buy Rating on PYXS and Reiterates $6 Price Target on Promising MICVO Data

TIPRANKS
·
Sep 10

Pyxis Oncology is Maintained at Overweight by Wells Fargo

Dow Jones
·
Sep 09